What’s the Role of the New Non-Opioid Analgesic in Pain Management in Older Adults?

Recently, the U.S. Food and Drug Administration approved suzetrigine (brand name Journavx; Vertex Pharmaceuticals) for the treatment of moderate to severe acute pain in adults. It received the Breakthrough Therapy, Fast Track, and Priority Review designations from the FDA (“FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain,” FDA News Release, Jan. 30, 2025, https://bit.ly/4kQbovY).